Synergistic Lethal Mutagenesis of Hepatitis C Virus | Zendy

Isabel Gallego | Zendy; María Eugenia Soria | Zendy; Josep Gregori | Zendy; Ana Isabel de Ávila | Zendy; Carlos GarcíaCrespo | Zendy; Elena Moreno | Zendy; Ignacio Gadea | Zendy; Jaime Esteban | Zendy; R. FernándezRoblas | Zendy; Juan Ignacio Esteban | Zendy; Jordi Gómez | Zendy; Josep Quer | Zendy; Esteban Domingo | Zendy; Celia Perales | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Synergistic Lethal Mutagenesis of Hepatitis C Virus

Author(s) -

Isabel Gallego,

María Eugenia Soria,

Josep Gregori,

Ana Isabel de Ávila,

Carlos GarcíaCrespo,

Elena Moreno,

Ignacio Gadea,

Jaime Esteban,

R. FernándezRoblas,

Juan Ignacio Esteban,

Jordi Gómez,

Josep Quer,

Esteban Domingo,

Celia Perales

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01653-19

Subject(s) - favipiravir , mutagenesis , virology , ribavirin , virus , biology , mutation , viral replication , mutant , hepatitis c virus , genetics , medicine , covid-19 , gene , disease , pathology , infectious disease (medical specialty)

Lethal mutagenesis is an antiviral approach that consists of extinguishing a virus by an excess of mutations acquired during replication in the presence of a mutagenic agent, often a nucleotide analogue. One of its advantages is its broad-spectrum nature, which renders the strategy potentially effective against emergent RNA viral infections. Here we describe the synergistic lethal mutagenesis of hepatitis C virus (HCV) by a combination of favipiravir (T-705) and ribavirin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research